Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9142460 | 1.00 | MAPT (0.50) | MAPTFFAR1KDM4ETDP1MAPK1 | |
| SCHEMBL23163644 | 0.85 | KDM4E (0.49) | MAPTKDM4ETDP1MAPK1GPR88 | |
| SCHEMBL9698630 | 0.84 | NPSR1 (0.49) | MAPTFFAR1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL10705795 | 0.83 | FFAR1 (0.53) | MAPTFFAR1KDM4EALDH1A1HPGD | |
| SCHEMBL10705801 | 0.83 | FFAR1 (0.53) | MAPTFFAR1KDM4EALDH1A1HPGD | |
| SCHEMBL11920836 | 0.82 | FFAR1 (0.51) | MAPTFFAR1KDM4EMEN1KMT2A | |
| SCHEMBL16572200 | 0.82 | KDM4E (0.49) | MAPTKDM4ETDP1MAPK1ALDH1A1 | |
| SCHEMBL940075 | 0.81 | MAPT (0.54) | MAPTKDM4ETDP1MAPK1ALDH1A1 | |
| SCHEMBL9237800 | 0.81 | FFAR1 (0.48) | MAPTFFAR1KDM4ETDP1MAPK1 | |
| SCHEMBL14528314 | 0.80 | FFAR1 (0.50) | MAPTFFAR1TDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287001-A1 | Organic Semiconducting Compounds | RAYNERGY TEK INC (TW) | 2023-09-14 | — | — | US | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-5399701-A | Polyfluoroalkyloxypyridinecarboxylic acid and -carboxaldehyde intermediates | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-5389290-A | Ferroelectric liquid crystalline materials | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0255236-B1 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING & MFG (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5254747-A | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0220297-B1 | NITROGEN-CONTAINING HETEROCYCLES | MERCK PATENT GmbH (DE) | 1991-12-11 | — | — | EP | disclosed |
| US-4886619-A | TILTED OR LATENT TILTED MESOPHASES; BLENDS; FERROELECTRIC DEVICE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| US-4834904-A | FERROELECTRIC LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-30 | — | — | US | disclosed |
| EP-0255236-A2 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-02-03 | — | — | EP | disclosed |
| EP-0220297-A1 | NITROGEN-CONTAINING HETEROCYCLES. | MERCK PATENT GMBH (DE) | 1987-05-06 | — | — | EP | disclosed |
| WO-1986006373-A1 | NITROGEN-CONTAINING HETEROCYCLES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287001-A1 | Organic Semiconducting Compounds | OCIAD2, OCIAD1, OSTC | MAPT 32/4885FFAR1 4065/4885KDM4E 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.